Carnitine deficiency is a condition where your body doesn’t have enough carnitine, a substance that acts as a shuttle for fat molecules, carrying them into the energy-producing centers of your cells. Without adequate carnitine, your body can’t efficiently burn fat for fuel, leading to energy shortages that can affect your heart, muscles, liver, and brain. It ranges from a rare genetic disorder present at birth to a more common acquired form triggered by medications, kidney problems, or other health conditions.
What Carnitine Does in Your Body
Your cells generate energy by breaking down fats and sugars. For long-chain fatty acids (the most common type of fat your body stores), there’s a catch: they can’t pass through the inner wall of mitochondria, the tiny power plants inside each cell, on their own. Carnitine binds to these fatty acids and physically carries them across that barrier. Once inside, the fat is released from carnitine, broken down through a multi-step process, and converted into usable energy. Carnitine then cycles back out to pick up more fatty acids.
This shuttle system matters most during fasting, prolonged exercise, or illness, when your body shifts from burning glucose to burning stored fat. If carnitine levels are too low, fat can’t get into the mitochondria. Instead, it accumulates in tissues like the heart, liver, and skeletal muscle. At the same time, glucose gets used up faster than normal because it becomes the only available fuel source. Your liver can’t produce ketones (the backup fuel your brain relies on during fasting), and blood sugar drops. The combination of no fat burning, no ketone production, and falling blood sugar is what makes severe carnitine deficiency dangerous.
Primary vs. Secondary Carnitine Deficiency
Carnitine deficiency falls into two categories with very different causes.
Primary Carnitine Deficiency
Primary carnitine deficiency (PCD) is a genetic condition caused by mutations in the SLC22A5 gene, which provides the blueprint for a protein called OCTN2. This protein sits on cell surfaces and pulls carnitine from the bloodstream into cells. It also works in the kidneys to recapture carnitine before it’s lost in urine. When OCTN2 doesn’t function properly, carnitine leaks out through the kidneys, blood levels drop, and cells can’t accumulate enough to keep fat metabolism running.
PCD is inherited in an autosomal recessive pattern, meaning a child must receive a defective copy of the gene from both parents to develop the condition. It occurs in roughly 1 in 100,000 newborns worldwide, though rates vary by region. In Japan, the incidence is about 1 in 40,000. Certain isolated populations also have higher rates. In the Faroe Islands, the condition is common enough that a postmortem study found 13 young people who had died suddenly were later identified through genetic testing as having undiagnosed PCD.
Secondary Carnitine Deficiency
Secondary carnitine deficiency is far more common and results from something else depleting your carnitine stores. The most well-known culprit is valproic acid (sold under brand names like Depakote), a widely used anti-seizure medication. Long-term or high-dose use depletes carnitine through several overlapping mechanisms, including interfering with how the kidneys reabsorb it. Other medications linked to carnitine depletion include cyclosporine (an immune suppressant), certain antibiotics, and some chemotherapy drugs.
Beyond medications, secondary deficiency can develop from kidney failure (since the kidneys regulate carnitine levels), malabsorption conditions that limit dietary intake, and certain inherited metabolic disorders that consume carnitine faster than normal.
Symptoms and How They Develop
Symptoms depend on how severe the deficiency is and which organs are most affected. In primary carnitine deficiency, problems typically surface in infancy or early childhood, though some people remain undiagnosed well into adulthood.
The most common presentations include:
- Muscle weakness: Skeletal muscles depend heavily on fat burning for sustained energy. Weakness in the arms and legs, poor exercise tolerance, and muscle pain are often early signs.
- Heart problems: The heart is one of the most fat-dependent organs in the body. Carnitine deficiency can cause the heart muscle to weaken and enlarge (cardiomyopathy) and trigger irregular heart rhythms. In severe, untreated cases, this can lead to sudden cardiac death.
- Low blood sugar episodes: During fasting or illness, the body can’t switch to fat burning. Blood sugar drops without the normal ketone backup, leading to what’s called hypoketotic hypoglycemia. In young children, this can cause seizures and loss of consciousness.
- Liver enlargement: Fat that can’t be burned accumulates in liver cells, causing the organ to swell and sometimes fail.
Milder forms, especially in adults, may show up mainly as exercise intolerance, recurrent muscle pain, or episodes of muscle breakdown (rhabdomyolysis) triggered by prolonged physical activity, fasting, or illness. Some adults with PCD have no symptoms at all until a metabolic crisis is triggered by stress on the body.
How It’s Diagnosed
Many countries now screen for primary carnitine deficiency as part of routine newborn blood spot testing. The key marker is free carnitine (abbreviated C0) measured from a few drops of blood on filter paper. When free carnitine falls below a threshold, typically around 5 to 10 micromoles per liter depending on the country’s protocol, further testing is triggered.
Follow-up usually involves a repeat blood test to rule out a false positive, since a newborn’s carnitine levels can be temporarily low if the mother has low levels. If carnitine remains low on retest, genetic sequencing of the SLC22A5 gene can confirm PCD. Some screening programs also use a functional test on skin cells to directly measure how well the OCTN2 transporter works. Countries like China, Norway, and Slovenia have started using genetic sequencing as an early step in the screening process to reduce false positives.
In older children and adults, diagnosis usually starts with a blood test showing low total and free carnitine levels, combined with symptoms. Urine testing can reveal whether the kidneys are losing excessive amounts of carnitine, which points toward a primary transporter problem rather than a secondary cause.
Treatment and Long-Term Outlook
The cornerstone of treatment for both primary and secondary carnitine deficiency is oral L-carnitine supplementation. For adults, a typical starting dose is around 1 gram per day, taken with food. Children receive weight-based dosing, generally starting at about 50 milligrams per kilogram of body weight per day, divided across meals. Your doctor adjusts the dose based on blood carnitine levels and symptom response.
For primary carnitine deficiency, supplementation is lifelong. The goal is to maintain carnitine levels high enough to keep fat metabolism functioning and prevent the dangerous energy crises that can damage the heart and brain. People with PCD also benefit from avoiding prolonged fasting and being especially careful during illness, when the body’s demand for fat burning increases.
The prognosis with consistent treatment is remarkably good. A 10-year follow-up study of patients in the Faroe Islands found that nearly all individuals diagnosed with PCD who were receiving L-carnitine supplementation were alive and doing well. The oldest patients in the study were 89 and 81 years old. Four patients had died during the follow-up period, but all from unrelated causes (lung cancer, breast cancer, heart failure in an 81-year-old, and chronic lung disease in an 86-year-old).
The contrast with untreated PCD is stark. At least 13 sudden deaths among young people in the Faroe Islands have been attributed to undiagnosed, untreated PCD, with the majority occurring in women. The sudden death of a young Faroese woman in 2009, diagnosed with PCD but not yet started on treatment, led to a public push for expanded newborn screening in the islands. This pattern underscores that PCD is a condition where a simple, inexpensive supplement can be the difference between normal life expectancy and fatal cardiac events.
For secondary carnitine deficiency, treatment involves addressing the underlying cause whenever possible, such as adjusting a medication dose, while supplementing carnitine to restore adequate levels. Once the trigger is removed or managed, carnitine levels often recover without the need for lifelong supplementation.